Last updated 2026-09-03
- Acquired by Advaxis for $280M, Jul 2021
- Raised $27M A Round Extension led by Biotel, Dec 2020
- Raised $19M Series A led by Arkin Bio Ventures, Mar 2020
Total raised
$59.0M
Last: Undisclosed Round 2020-12
Stage
Acquired
Founded
2000
Headcount
3
HQ
Lod, Israel
Sector
Pharmaceuticals
About
BioSight is an Israeli biopharmaceutical company focused on developing innovative cancer therapeutics that enhance treatment efficacy while minimizing side effects through advanced drug delivery systems. The company specializes in developing novel cancer therapeutics, focusing on enhancing treatment outcomes for patients with various malignancies. BioSight is known for its proprietary drug delivery platform, which optimizes the therapeutic index of chemotherapeutic agents. Its flagship product targets specific cancer types and aims to address unmet medical needs in oncology. BioSight serves oncologists, hospitals, and research institutions primarily in North America and Europe.
Funding history · 4 rounds · $59.0M total
4 events/rounds · $59.0M Total Funding: $59.0M in Private Equity
Sep 2023
★ certain current shareholders and third parties
Dec 2020
Mar 2020
★ Arkin Bio Ventures★ SBI JI Innovation Fund★ Israel Biotech Fund (IBF)★ additional new and existing investors
May 2016
Offices
Lod, Israel · HQ / main office
Q&A
- What is BioSight's current status?
- BioSight was acquired by Ayala Pharmaceuticals in October 2023 and is currently inactive.
- What was the most recent acquisition event for BioSight?
- In July 2023, Ayala Pharmaceuticals and BioSight entered into a definitive merger agreement. The combined company would operate under the name Ayala Pharmaceuticals, Inc.
- What was the acquisition amount when Advaxis acquired BioSight?
- In July 2021, BioSight was acquired by Advaxis for $280,000,000.
- What was the total amount raised by BioSight?
- BioSight raised a total of $62,500,000 USD across all funding rounds.
- What was the purpose of the Phase 1/2 clinical trial launched by BioSight in November 2022?
- In November 2022, BioSight launched a Phase 1/2 clinical trial to evaluate the safety and efficacy of its lead asset, aspacytarabine (BST-236), in combination with venetoclax for induction therapy of newly-diagnosed Acute Myeloid Leukemia (AML) patients unfit for standard chemotherapy.
- Did BioSight receive any special designations for its lead product BST-236?
- Yes, in August 2020, BioSight was granted U.S. FDA Fast Track Designation for BST-236 for the treatment of acute myeloid leukemia (AML) in adults 75 years or older or with comorbidities precluding intensive induction chemotherapy. Additionally, in June 2019, BioSight received Orphan Drug Designation from the FDA for BST-236 for the treatment of AML.
- Who led BioSight's Series C funding round in March 2020?
- The Series C funding round of $46,000,000 in March 2020 was led by Israel Biotech Fund (IBF).
Team · 13
Dr. Stella Gengrinovich
Founder · Founder
Pini Orbach
Chairman
Gary Gordon
Director
Yuval Cabilly
Director
Gary Titus
Director
Jacob M. Rowe
Chairman, Clinical Advisory Board
Martin S. Tallman
Advisor
Pierre Fenaux
Advisor
Selina M. Luger
Advisor
Eytan M. Stein
Advisor
Tsila Zuckerman
Advisor
Dr. Ruth Ben Yakar
CEO
Roy Golan
Chief Financial Officer
Sectors & technology
Primary sector
Pharmaceuticals
Target customers
Business model
Licensing agreementsMilestone payments
Highlights
1 Patents
Tags
chemotherapycancerdrug-discoverybiopharmaceuticaltargeted-therapypharmaceuticalscancer-therapyoncologyhematology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | biosight-pharma.com |
|---|---|
| linkedin.com/company/9423263 |
Identifiers & details
| Legal name | BioSight Ltd. |
|---|---|
| Founded | 2000 |
| Employees (exact) | 3 |
| Status reason | Acquired (Inactive) by Ayala Pharmaceuticals on Oct 2023 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Advaxis 2021-07 $280.0M
Radar intelligence
Patents
| EPO | 16 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | biosight-pharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512852559 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 1999-11-10 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2023 |
| Active charges / liens | 0 |
| Registry events | 1 — violation (1) |
| Registered address | הירדן 3 קריית שדה התעופה |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-25 | עדכון הפרה |